Pharm-Olam's response to COVID-19 from CEO Rob Davie, PhD. Read Here
Check out our latest white paper! We partnered with Informa Pharma Intelligence to bring you the latest information on COVID-19 and its effect on the clinical landscape.
The United Kingdom officially withdrew from the European Union (EU) on Jan 31, 2020. They have until Dec 31, 2020 to complete...
Pharm-Olam, as a global CRO, has over 20 years' experience conducting clinical trials in Central and Eastern Europe (CEE). In...
Pharm-Olam is an allergy focused CRO and have worked on over 35 allergy clinical trials. In this article, we explore the area...
Effective Data management plays a critical role in the conduct of clinical trials. Clinical research requires quality data...
Pharm-Olam is a clinical research organization (CRO) that has vast experience in rare diseases. To date, we have completed...
Pharm-Olam is a clinical research organization (CRO) with global reach and deep expertise in rare disease research. Our...
Tags: Rare & Orphan Disease
Conducting Phase I studies is always complex. At this stage in clinical research, you are examining the tolerability of the...
In a world with COVID-19, remote monitoring is now essential to effectively monitor studies. Sponsors and CROs are either...
Tags: Pharm-Olam Insights, COVID-19
Subscribe to our blog and we'll give you our GDPR Controller & Processor Checklist.
